0001209191-21-023868.txt : 20210331
0001209191-21-023868.hdr.sgml : 20210331
20210331191139
ACCESSION NUMBER: 0001209191-21-023868
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210330
FILED AS OF DATE: 20210331
DATE AS OF CHANGE: 20210331
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Thompson Peter A.
CENTRAL INDEX KEY: 0001357522
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40236
FILM NUMBER: 21795312
MAIL ADDRESS:
STREET 1: C/O ANTHERA PHARMACEUTICALS, INC.
STREET 2: 25801 INDUSTRIAL BOULEVARD, SUITE B
CITY: HAYWARD
STATE: CA
ZIP: 94545
FORMER NAME:
FORMER CONFORMED NAME: Thompson Peter A
DATE OF NAME CHANGE: 20060327
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Edgewise Therapeutics, Inc.
CENTRAL INDEX KEY: 0001710072
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 821725586
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: C/O ORBIMED ADVISORS LLC
STREET 2: 601 LEXINGTON AVE, 54TH FLR.
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: 212-739-6451
MAIL ADDRESS:
STREET 1: C/O ORBIMED ADVISORS LLC
STREET 2: 601 LEXINGTON AVE, 54TH FLR.
CITY: NEW YORK
STATE: NY
ZIP: 10022
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-03-30
0
0001710072
Edgewise Therapeutics, Inc.
EWTX
0001357522
Thompson Peter A.
C/O EDGEWISE THERAPEUTICS, INC.
3145 COLORADO AVE.
BOULDER
CO
80303
1
0
1
0
Common Stock
2021-03-30
4
C
0
12730036
0.00
A
13046956
I
See Footnotes
Common Stock
2021-03-30
4
C
0
272724
0.00
A
272724
I
See Footnotes
Common Stock
2021-03-30
4
P
0
46875
16.00
A
319599
I
See Footnotes
Common Stock
2021-03-30
4
P
0
312500
16.00
A
13359456
I
See Footnotes
Series A Preferred Stock
0.00
2021-03-30
4
C
0
8187100
0.00
D
Common Stock
8187100
0
I
See Footnotes
Series B-1 Preferred Stock
0.00
2021-03-30
4
C
0
1572960
0.00
D
Common Stock
1572960
0
I
See Footnotes
Series B-2 Preferred Stock
0.00
2021-03-30
4
C
0
1301626
0.00
D
Common Stock
1301626
0
I
See Footnotes
Series C Preferred Stock
0.00
2021-03-30
4
C
0
1668350
0.00
D
Common Stock
1668350
0
I
See Footnotes
Series C Preferred Stock
0.00
2021-03-30
4
C
0
272724
0.00
D
Common Stock
272724
0
I
See Footnotes
Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock and Series C Preferred Stock converted into one share of the Issuer's Common Stock immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.
These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationship, OrbiMed Advisors and GP VI may be deemed to have voting power and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VI.
These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationship, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by Genesis.
/s/ John R. Moore Attorney-in-Fact for Peter Thompson M.D.
2021-03-31